Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial.

[1]  M. Balaan,et al.  Acute Respiratory Distress Syndrome , 2016, Critical care nursing quarterly.

[2]  M. Matthay,et al.  Microvesicles Derived From Human Mesenchymal Stem Cells Restore Alveolar Fluid Clearance in Human Lungs Rejected for Transplantation , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  M. Matthay,et al.  Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis. , 2014, The Lancet. Respiratory medicine.

[4]  K. Delucchi,et al.  Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome , 2014, Annals of Intensive Care.

[5]  D. Prough,et al.  Human mesenchymal stem cells reduce the severity of acute lung injury in a sheep model of bacterial pneumonia , 2014, Thorax.

[6]  F. Guo,et al.  The effect of prone positioning on mortality in patients with acute respiratory distress syndrome: a meta-analysis of randomized controlled trials , 2014, Critical Care.

[7]  Hye Soo Yoo,et al.  Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial. , 2014, The Journal of pediatrics.

[8]  J. Laffey,et al.  Translational Research in Acute Lung Injury and Pulmonary Fibrosis Clinical grade allogeneic human mesenchymal stem cells restore alveolar fluid clearance in human lungs rejected for transplantation , 2014 .

[9]  Q. Shu,et al.  Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study , 2014, Respiratory Research.

[10]  M. Matthay,et al.  Is there still a role for the lung injury score in the era of the Berlin definition ARDS? , 2014, Annals of Intensive Care.

[11]  S. Jaber,et al.  Prone positioning in severe acute respiratory distress syndrome. , 2013, The New England journal of medicine.

[12]  R. Casaburi,et al.  A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. , 2013, Chest.

[13]  N. Ferguson,et al.  Clinical review: Acute respiratory distress syndrome - clinical ventilator management and adjunct therapy , 2013, Critical Care.

[14]  M. Matthay,et al.  Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. , 2013, American journal of respiratory and critical care medicine.

[15]  Arthur S Slutsky,et al.  Acute Respiratory Distress Syndrome The Berlin Definition , 2012 .

[16]  B. Thompson,et al.  Plasma angiopoietin-2 in clinical acute lung injury: Prognostic and pathogenetic significance* , 2012, Critical care medicine.

[17]  M. Matthay,et al.  Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. , 2012, American journal of physiology. Lung cellular and molecular physiology.

[18]  D. Rowlands,et al.  Mitochondrial transfer from bone-marrow–derived stromal cells to pulmonary alveoli protects against acute lung injury , 2012, Nature Medicine.

[19]  M. Matthay,et al.  Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia , 2012, Thorax.

[20]  J. Laffey,et al.  Mesenchymal stem cells enhance recovery and repair following ventilator-induced lung injury in the rat , 2011, Thorax.

[21]  M. Matthay,et al.  Concise Review: Mesenchymal Stem Cells for Acute Lung Injury: Role of Paracrine Soluble Factors , 2011, Stem cells.

[22]  M. Matthay,et al.  Antibacterial Effect of Human Mesenchymal Stem Cells Is Mediated in Part from Secretion of the Antimicrobial Peptide LL‐37 , 2010, Stem cells.

[23]  Arthur S Slutsky,et al.  Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. , 2010, American journal of respiratory and critical care medicine.

[24]  A. Loundou,et al.  Neuromuscular blockers in early acute respiratory distress syndrome. , 2010, The New England journal of medicine.

[25]  Jae W. Lee,et al.  Allogeneic Human Mesenchymal Stem Cells Restore Epithelial Protein Permeability in Cultured Human Alveolar Type II Cells by Secretion of Angiopoietin-1*♦ , 2010, The Journal of Biological Chemistry.

[26]  Jae W. Lee,et al.  Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung , 2009, Proceedings of the National Academy of Sciences.

[27]  P. Parsons,et al.  Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury , 2008, Thorax.

[28]  Jae W. Lee,et al.  Intrapulmonary Delivery of Bone Marrow-Derived Mesenchymal Stem Cells Improves Survival and Attenuates Endotoxin-Induced Acute Lung Injury in Mice1 , 2007, The Journal of Immunology.

[29]  L. Ortiz,et al.  Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury , 2007, Proceedings of the National Academy of Sciences.

[30]  Gordon R Bernard,et al.  Comparison of two fluid-management strategies in acute lung injury. , 2006, The New England journal of medicine.

[31]  G. Bernard,et al.  Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury* , 2005, Critical care medicine.

[32]  J. Vincent,et al.  Serial evaluation of the SOFA score to predict outcome in critically ill patients. , 2001, JAMA.

[33]  D. Schoenfeld,et al.  Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. , 2000, The New England journal of medicine.

[34]  Y. Matsuzawa,et al.  A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. , 2000, The New England journal of medicine.

[35]  J. Vincent,et al.  The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure , 1996, Intensive Care Medicine.

[36]  J F Murray,et al.  An expanded definition of the adult respiratory distress syndrome. , 1988, The American review of respiratory disease.

[37]  M. Mathru.  Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung , 2010 .

[38]  Krisztián Németh,et al.  Bone marrow stromal cells attenuate sepsis via prostaglandin E2–dependent reprogramming of host macrophages to increase their interleukin-10 production , 2009, Nature Medicine.